Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Big yep upcoming news is an issue for sure like every stock. For now it is wait and see if they have any follow up. If not my stops are in if so fine. lol Either way I am sure glad I was not shorting it!
DARA When that much of a float trades at a new price that should become a new pricing area for it imho.
1/2 the shares are buy and 1/2 are sells of the trade volume but those buys represent 1.9M shares. Based on a 6M float that is around 30% or nearly 1/3 of the O/S at the new price area. If the volume continues then the strength of the support also grows for this new pricing,
I think it is a good bet, but then I am a current holder so that generates a natural bias. lol
DARA A huge part of this tiny float has turned over this a.m. with 3.4M shares. Based on the Yahoo O/S number or the Finviz # which ever is used
6.12M share O/S
http://finance.yahoo.com/q/ks?s=DARA+Key+Statistics
DARA Legacy I am looking to see if there is some covering before too long; that seldom comes immediately when a stock gaps way up, unless it is called for some reason, love to see that. I am hoping though that there will be some follow through and somewhat of a near term cover. Imho just depends on what other things the company has in its bag to throw out.
Thus far the part I bought back after I sold out has not been a stellar move. lol Fortunately, I only bought back about 40% of what I sold out AH share wise, so I am still very green on the net trade. Have to see what the near term doles out.
BOL You sound like you are in it for a bit longer ride, expecting much closer to that PT, while I am in it for a flip far more modest gains perspective.
T2M
Yup only 6.20+ more and it would have lol. I would be happy to see a 2x today's close tomorrow.
nywest your guess is as good as mine, It will be interesting for sure.
nywest - yes same date with the same designation. Most probably it will either be release premarket or near the open for DARA, that is my guess but who knows/.
DARA should go nuts with this sort of announcement due to ultra tiny o/s & float, and if the shorts are heavy in it like they used to be they will try to cover. Finviz pegged them as 40% shot of float
http://finviz.com/quote.ashx?t=dara
Yahoo has 12% short of float maybe b4 and after r/s?
http://finance.yahoo.com/q/ks?s=DARA+Key+Statistics
Should be interesting
Fara how many shares are you short? They just did an R/S
Dated 2/21 that was last Friday I believe.
DARA 5M O/S That recent R/S made this an incredibly small O/S, Yahoo has a 6M o/s and Finviz has 5M either way it is tiny. This should move fast
http://finance.yahoo.com/q/ks?s=DARA+Key+Statistics
DARA The best part is the miniscule O/S it has wow, only 5m shares.
Ended up buying some back 1/2 of what I sold, in another account @ $3.6 due to 5M O/S.
This should move like a feather!
jmho
P - Kudos on the profit, I'm not one either who resists a 30-50% profit in a couple weeks. KUDOS
DARA Afterhours profit exit 30%. Now will review later.
Kei the volume is actually very close to the 20MA for volume so it is a decent day. but not yet exceptional yet for volume. Having said that whatever moves it makes (on the close) as such should be somewhat indicative.
1,382,849 is the 20 Ma for trading volume and we are pretty much right there
1,361,400 being traded as I write today.
Personally I would like to see it 20% higher than 20MA volume for a session and green at the close. That would indicate a potential wake up. Guess we shall see. Hope so but it has a long way to go yet.
BOL
T2M
Pack more likely it is reacting to the DOW being up 187 pts today, all boats rise with a higher tide.
pack- just follow the money - CLNE is heavily shorted and has been for a long time. This type of written misinformation is always put out to either contribute to a dip or to try and create one. Unfortunately the shorts have controlled this stock for a long time and will likely until the B/E is achieved or some stock dividend is issued; I prefer the later.
Littlefield's interview on the subject flies in the face of much of this, albeit not entirely. Keep in mind a great SHORT story has about 40% truth and then 60% short spin BS. Folks are more easily scared out of stocks mentally then pushed into them, and that is the mindset most Shorts rely on.
I doubt seriously if the #1 in its industry is going anywhere longer term, in the mean time I will continue to lower my cost basis here and there courtesy of the shorts.
If I recall Littlefield was projecting good numbers for 2014 regardless of the shorts of the world. lol
Shorts are many times an issue for companies who do not actively fight them and CLNE obviously does not and never has imo.
NEPT & ACST <link back> seems that article you posted Friday is helping both Sheff.
http://seekingalpha.com/article/2038643-chen-lins-perfect-biotech-market-prescription-buy-low-sell-high?source=yahoo
IGXT nice news today
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 24, 2014
Date of Report (Date of Earliest Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware 000-31187 870638336
(State or other jurisdiction of (Commission File (IRS Employer Identification
incorporation) Number) No.)
6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (514) 331-7440
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
Exhibit Description
99.1 Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
Dated: February 24, 2014 By: /s/ Rajiv Khosla
Rajiv Khosla
President and Chief
Executive Officer
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
Saint Laurent, Quebec, - (Newsfile Corp. - February 24, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (“IntelGenx”), a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm™ tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.
This was a randomized, two-period, two-way crossover study in healthy male subjects. The study was designed to determine whether VersaFilm™ tadalafil was bioequivalent as measured by industry standard pharmacokinetic measures of peak plasma concentration (Cmax) and area under the curve (AUC). The study results demonstrated that VersaFilm™ tadalafil was within an acceptable range of bioequivalency with the RLD on both of these measures.
“The completion of this pilot biostudy confirms that we can continue the development of our VersaFilm™ tadalafil product” said Rajiv Khosla, IntelGenx' President and CEO. "We now plan to progress this project, leading to a pivotal bioequivalence study, with the objective of filing a 505(b)(2) NDA with the U.S. Food and Drug Administration."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
IGXT Nice news today:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 24, 2014
Date of Report (Date of Earliest Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware 000-31187 870638336
(State or other jurisdiction of (Commission File (IRS Employer Identification
incorporation) Number) No.)
6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (514) 331-7440
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
Exhibit Description
99.1 Press Release
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
Dated: February 24, 2014 By: /s/ Rajiv Khosla
Rajiv Khosla
President and Chief
Executive Officer
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
Saint Laurent, Quebec, - (Newsfile Corp. - February 24, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (“IntelGenx”), a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm™ tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.
This was a randomized, two-period, two-way crossover study in healthy male subjects. The study was designed to determine whether VersaFilm™ tadalafil was bioequivalent as measured by industry standard pharmacokinetic measures of peak plasma concentration (Cmax) and area under the curve (AUC). The study results demonstrated that VersaFilm™ tadalafil was within an acceptable range of bioequivalency with the RLD on both of these measures.
“The completion of this pilot biostudy confirms that we can continue the development of our VersaFilm™ tadalafil product” said Rajiv Khosla, IntelGenx' President and CEO. "We now plan to progress this project, leading to a pivotal bioequivalence study, with the objective of filing a 505(b)(2) NDA with the U.S. Food and Drug Administration."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
You made out like a bandit. lol
CN I have been holding AGQ and NUGT and they have done quite well as Silver and Gold climb. Not sure quite as well as yours but decent. lol
Wildcard On this, as most, there is a catalyst with a date, but locking in profits as you know is always a good thing. Reentering on a pull back is many times also a good thing. In our bio world when you have a catalyst there is normally a run up of some sort months prior prior and we try to get on and ride for a while, then take profits and perhaps reenter, or perhaps not.
17% on a short hold is one I will take most times myself, as would many, assuming I am lucky enough to get there. I am not a buy and hold sort, and many on the board, including Sheff are not here really for that. Lots of turnover and decent gains should generate a good year end gain.
So that is why doing what he did is what many of us would love to do. Holding merely invites retrace, so why not sell at a set % gain, then just reenter and have greater gains.
Everyone trades differently, and we all wish each other the best of luck.
Jmho
T2M
CN while it won't be that 4x your money, it should do fine imo.
Kudos on the other one!
T2M
Taking profits is 100% fine imo lol and 17% is a Sweet Spot. My entry didn't afford me that due to an earlier stop out, so hopefully I am reading the chart correctly, needs to break/violate that "middle" resistance tine on the chart pitchfork, then I will be much happier. Long as earnings are good then it should not be a problem.
Big Kudos though on the bird in the hand you have vs my bird in the bush.
Lots are following you from the looks of the trading after your post.
It may well provide me an opportunity. Thanks much.
BOL
Sheff - Thanks for the articles, they are not normally on the sites I track. Although I guess they should be. lol
PBMD I keep a core and have flipped 3x on it. This bio currently working on ovarian cancer. Its recent tests are plussss and it has a nice chart coming off a 3x bottom in a bullish northern trend.
http://finance.yahoo.com/news/prima-biomeds-004-clinical-trial-220000598.html
http://finviz.com/quote.ashx?t=pbmd
PBMD I keep a core on this bio currently working on ovarian cancer. Its recent tests are plussss and it has a nice chart coming off a 3x bottom in a bullish northern trend.
http://finance.yahoo.com/news/prima-biomeds-004-clinical-trial-220000598.html
http://finviz.com/quote.ashx?t=pbmd
NEPT & ACRX Hold both of these. Chenn had a good article thanks Sheff
MSTX Bullish Article but it may take time. jmho
http://finance.yahoo.com/news/mast-therapeutics-provides-additional-results-130000152.html
SGYP Exited one account with 8.3% profit but also today entered in another account. Total didn't change much still 8.3% ahead, but accounts changed. Make that 9.96% as of tonight.
Traded very well today on strong volume and up 9.6%. It just spun off a stock CTRV dividend to us but that stock is down from the spin off the other day.
It deals with shingles.
PGNX For now it is an open ended offering without definite # of shares announced. In the past they have had rather significant offerings according to yahoo and if it follows suit they will need some time to recover most likely. Other than an unspecified delayed Adcom which as Sheff points out is just as likely 4th Qtr, I see no immediate catalyst, so cash burn must have played a factor. jmho probably plenty of time to revisit it if once chooses.
jmho
SYN - SYN..Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst http://t.co/YWkZybWWMs … $HALO $POZN $PRAN $TEVA $SYN
DRTX BS 15+ by 3/31 is my bet also. It is doing nicely with a slow ratchet up.
Bol
T2M
It came up on the news report at Schwab as "Deleted MW Chealsea... are halted" and seemed without trades, then started trading again shortly afterward. I didn't see any resumption alert, so not sure of what exactly that meant/ Guess it is not a regular halt where they have a "trade resumed" announcement etc
CHTP Trading halted as of now??
CHTP Big Kudos to those CHTPers who held, nice AH trading